Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

562
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
562
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

1.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Drug Clearance: Overview01:06

Drug Clearance: Overview

123
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
123
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Salvianolic acid B attenuates drug-induced liver injury in an Nrf2-dependent mechanism via covalently modifying Keap1 at Cys395/Cys434.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Highly efficient discovery of CYP1B1 inhibitors from licorice as novel anti-fibrotic agents via integrating interdisciplinary methodologies.

Toxicology and applied pharmacology·2026
Same author

A flexible antigen-presenting cell targeting lentinan immunomodulator promotes stimulator of interferon gene-driven cancer therapy.

Carbohydrate polymers·2026
Same author

A Rationally Engineered MAGL-Activatable Fluorogenic Probe Enables Efficient Discovery of Anti-Inflammatory and Hepatoprotective Agents.

Journal of medicinal chemistry·2026
Same author

Erratum: Matrine suppresses lung cancer metastasis <i>via</i> targeting M2-like tumour-associated-macrophages polarization.

American journal of cancer research·2026
Same author

Mechanistic study on the holistic actions of Hong-Hua-Xiao-Yao Tablet in alleviating premenstrual syndrome in rats.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Related Experiment Video

Updated: Jul 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K

CYP1A inhibitors: Recent progress, current challenges, and future perspectives.

Ziru Dai1, Yue Wu2, Yuan Xiong2

  • 1Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Medicinal Research Reviews
|June 20, 2023
PubMed
Summary
This summary is machine-generated.

Human cytochrome P450 1A (CYP1A) enzymes activate procarcinogens. CYP1A inhibitors offer promising cancer chemoprevention and can overcome drug resistance, aiding therapeutic development.

Keywords:
CYP1A1CYP1A2cytochrome P450inhibitorsstructure-activity relationships (SARs)

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Experiment Videos

Last Updated: Jul 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Mammalian cytochrome P450 1A (CYP1A) enzymes are crucial for metabolizing xenobiotics, drugs, and endogenous compounds.
  • The human CYP1A subfamily (hCYP1A1 and hCYP1A2) activates environmental procarcinogens into carcinogenic forms.
  • CYP1A inhibitors are explored for cancer chemoprevention and managing drug toxicity/resistance.

Purpose of the Study:

  • To review recent advancements in the discovery and characterization of human CYP1A (hCYP1A) inhibitors.
  • To analyze structural features, structure-activity relationships, and biomedical applications of hCYP1A inhibitors.
  • To identify challenges and future directions in hCYP1A inhibitor research.

Main Methods:

  • Comprehensive summary of reported hCYP1A inhibitors, including inhibition potentials, modes, and constants.
  • In-depth analysis of structural features and structure-activity relationships for hCYP1A1 and hCYP1A2 inhibitors.
  • Review of discovery approaches and biomedical applications.

Main Results:

  • Detailed summary of inhibition data for various hCYP1A inhibitors.
  • Analysis of structure-activity relationships for different classes of hCYP1A1 and hCYP1A2 inhibitors.
  • Identification of key structural determinants for inhibitory activity.

Conclusions:

  • hCYP1A inhibitors represent a promising therapeutic strategy for cancer chemoprevention and overcoming drug resistance.
  • Further research into hCYP1A inhibitors will facilitate the development of effective chemo-preventive agents and research tools.
  • This review provides valuable insights for researchers in the field of CYP1A inhibitor discovery and development.